Compare FTRE & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTRE | DRTS |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2023 | 2021 |
| Metric | FTRE | DRTS |
|---|---|---|
| Price | $18.13 | $14.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $14.06 | $8.67 |
| AVG Volume (30 Days) | ★ 1.6M | 492.6K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,723,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.09 | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $8.31 | $3.18 |
| 52 Week High | $21.39 | $15.02 |
| Indicator | FTRE | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 63.87 |
| Support Level | $16.92 | $6.47 |
| Resistance Level | $21.39 | $14.75 |
| Average True Range (ATR) | 0.90 | 0.61 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 51.00 | 87.42 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.